- Home
- / Oryzon Genomics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Oryzon Genomics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
€1.7
2024-10-29
Market Capitalization
€107 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of goods sold | 292.0K | 431.0K | 526.0K | 746.0K | 464.0K | 243.0K | 302.0K | 282.0K |
| Gross profit | 68.0K | (389.0K) | (428.0K) | (578.0K) | (209.0K) | (90.0K) | (89.0K) | 434.0K |
| Operating expense total | 2.8M | 3.3M | 3.7M | 6.3M | 5.1M | 4.3M | 4.2M | 6.0M |
| Depreciation and amortization | 150.0K | 149.0K | 145.0K | 144.0K | 167.0K | 153.0K | 148.0K | 134.0K |
| EBITDA | (2.8M) | (3.7M) | (4.1M) | (6.9M) | (5.3M) | (4.4M) | (4.3M) | (5.6M) |
| EBIT | (2.9M) | (3.8M) | (4.3M) | (7.0M) | (5.5M) | (4.5M) | (4.4M) | (5.7M) |
| Interest income | 3.0K | 16.0K | ||||||
| Interest expense | 804.0K | 772.0K | 469.0K | 456.0K | 1.1M | 1.9M | 1.2M | 608.0K |
| Pre tax profit | (3.7M) | (4.6M) | (4.8M) | (7.2M) | (6.6M) | (6.1M) | (5.6M) | (5.6M) |
| Income tax expense | (2.5M) | (892.0K) | (1.4M) | (2.5M) | (2.3M) | (2.8M) | (1.9M) | (3.0M) |
| Net Income | (1.2M) | (3.7M) | (3.4M) | (4.7M) | (4.2M) | (3.4M) | (3.7M) | (2.6M) |